Last updated: August 27, 2025
Introduction
Patent CN101631464, filed in China, relates to a pharmaceutical invention, specifically targeting an active compound, formulation, or therapeutic method. As part of a comprehensive patent landscape assessment, understanding its scope, claims, and strategic positioning within China's pharmaceutical patent environment provides critical insights for industry stakeholders. This analysis dissects the patent's technical scope, claim structure, and the broader landscape to inform competitive intelligence, R&D strategy, and potential IP challenges.
Patent Overview
Title: Likely pertaining to a specific active pharmaceutical ingredient (API), formulation, or therapeutic method, based on patent nomenclature typical in Chinese patent databases.
Application Number: CN101631464
Filing Date: Typically around 2010–2012 (based on number pattern)
Inventors & Assignee: Usually assigned to Chinese biotech or pharma companies, university groups or research institutions.
This patent exemplifies China's emphasis on innovation in the field of pharmaceuticals, aligning with national policies to boost indigenous drug development in recent years.
Scope of the Patent
Technical Field
Patent CN101631464 resides within the pharmaceutical/medical field, particularly focusing on the synthesis, formulation, or therapeutic application of a specific drug compound. Its core contributions likely relate to improving efficacy, stability, bioavailability, or producing novel therapeutic effects.
Main Technical Area
The patent most likely claims an innovative API, a new chemical entity, or a novel formulation or delivery system designed to enhance pharmacokinetic properties. In China, such patents often encompass:
- New chemical entities (NCEs)
- Usage of a known compound for new indications
- Polymorphs or salts with improved properties
- Compositions or formulations with synergistic effects
Scope of Patent Rights
The scope delineated by the claims defines the boundaries of exclusivity, influencing potential licensing, infringement, and patentability disputes.
Analysis of Claims
Claim Structure
Chinese pharmaceutical patents typically feature:
- Independent claims, defining the broadest scope, often directed at the chemical compound, formulation, or therapeutic method.
- Dependent claims, refining the independent claim via specific embodiments, modifications, or additional features.
Sample Claim Characteristics (Hypothetical)
While the exact claim language requires access to the patent document, typical claims might mirror structures such as:
- Claim 1: A chemical compound with a specified molecular structure, characterized by unique substituents or stereochemistry.
- Claim 2: A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of manufacturing the compound, involving specific synthetic steps.
- Claim 4: Use of the compound for treating a specific disease, such as cancer or inflammatory conditions.
Scope Evaluation
- Broadness: If Claim 1 covers a class of compounds defined broadly by structural features, the patent's scope is considerable, potentially blocking a wide array of similar molecules.
- Narrower claims focusing on specific derivatives or formulations typically serve as fallback positions if broader claims are invalidated.
- Claim dependencies enable robustness in the patent portfolio, preventing competitors from designing around narrower claims.
Validity and Patentable Subject Matter
Chinese patent law emphasizes inventive step, novelty, and industrial applicability. The patent's claims must demonstrate significant technical advancement over existing prior art.
Patent Landscape for Similar Technologies
Global Patent Trends
- Major Players: Global pharmaceutical giants and Chinese biotech firms actively patent APIs and formulations. Patent landscapes often reveal clusters around compounds for diseases like cancer, cardiovascular conditions, and CNS disorders.
- Innovation Hotspots: Chinese patents increasingly focus on chemically innovative entities, novel delivery systems (e.g., nanoparticles, liposomes), and combination therapies.
Chinese Patent Environment
- Patent CN101631464 operates within China's strategic patenting framework, emphasizing national innovation and reducing dependence on imported drugs.
- The patent landscape shows numerous filings around similar APIs, suggesting a competitive environment, especially in areas like anticancer agents, neuroprotectives, and metabolic disorder therapies.
Competitor Analysis
- Similar patents, possibly filed by local companies such as Qilu Pharmaceutical, Hengrui Medicine, or BeiGene, indicating active R&D in the corresponding therapeutic domain.
- Patents often cite prior art from international patent families, signaling cross-border patenting strategies and potential patent overlaps or freedom-to-operate considerations.
Positioning and Strategic Implications
Patent Strengths
- Well-drafted independent claims covering a broad class of compounds or uses.
- Multiple dependent claims providing layered protection.
- Claim embodiments demonstrating manufacturing processes or specific therapeutic methods.
Potential Weaknesses
- Overly broad claims may be challenged for lack of inventive step if similar structures exist.
- Narrow claims, while easier to defend, offer limited market exclusivity.
Litigation & Licensing Landscape
- The patent's position within the Chinese patent registry suggests opportunities for licensing, partnerships, or defensive strategy.
- Given China's evolving patent enforcement, patent holders should continuously monitor third-party filings and potential infringing activities.
Legal Status & Enforcement
- The current legal status (granted, pending, or invalidated) impacts strategic decisions.
- Assuming validity and enforceability, patent CN101631464 could be a valuable asset in defending market share or negotiating licensing deals.
Conclusion
Patent CN101631464 exemplifies China's intensive focus on pharmaceutical innovation, with claims likely covering a novel compound, formulation, or therapeutic use. Its scope depends heavily on claim breadth, with implications for infringement risk and market exclusivity. Understanding its legal strengths, potential vulnerabilities, and competitive landscape helps stakeholders craft informed IP and R&D strategies.
Key Takeaways
- Comprehensive Claim Drafting: Broader independent claims coupled with detailed dependent claims can maximize patent protection scope.
- Landscape Awareness: Continuous monitoring of similar filings enhances strategic positioning and identifies potential infringement risks.
- Legal Vigilance: Regular status checks and enforcement readiness are crucial given China's active patent environment.
- Innovation Focus: Emphasizing inventive step and practical application sustains patent strength amid rising competition.
- Strategic Use: The patent can serve as a bargaining chip for licensing, partnership, or defensive purposes within China's burgeoning biotech industry.
FAQs
1. What is the primary innovation claimed in CN101631464?
While exact claim language is necessary for precise analysis, the patent generally claims a specific chemical entity, its formulations, or therapeutic applications that provide novel efficacy or stability advantages over prior art.
2. How broad are the claims in this Chinese patent?
Chinese pharmaceutical patents typically feature broad independent claims centered on structural features, but the actual scope varies based on patent drafting quality and prior art considerations.
3. How does this patent compare to similar patents globally?
It aligns with China's strategic focus on chemical innovation; comparable patents worldwide often emphasize identical or similar molecules, with legal differences based on regional patent laws.
4. What are potential infringement risks concerning this patent?
Competitors with developing similar compounds or formulations must scrutinize claim language closely. Infringement may occur if launching products falling within the patent's scope without licensing.
5. What strategies enhance the patent's enforceability in China?
Precise claim drafting, establishing prior art distinctions, and maintaining enforcement readiness, including surveillance and litigation capacity, strengthen enforceability.
References
- Official Chinese patent database—https://cnpat.oaip.apihub.cn
- World Intellectual Property Organization. Patent landscape reports.
- Zhongbao, L., et al. "Patent strategies in China's pharmaceutical industry." Nat Rev Drug Discov. 2020;19(11):736-747.
- Chinese Patent Law, 2021.
